Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Comprehensive Analysis of Ozanimod-Related Adverse Events Based on th… Ozanimod · PMID 42490845 | Hypertension artérielle · Sclérose en plaques · Cancer | Traitement symptomatique | Publication | PubMed | Voir la publication source Ozanimod, a selective sphingosine-1-phosphate receptor modulator, has been approved for the treatment of moderately to… | World journal of oncology 2026-08-16 21:21:54 | Source |
| Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory B… Ozanimod · PMID 42595931 | Sclérose en plaques | Immunomodulation | Publication | PubMed | Voir la publication source Despite considerable advancements in the therapeutic landscape of inflammatory bowel disease (IBD) for adults, long del… | Paediatric drugs 2026-08-16 21:21:54 | Source |
| Ozanimod and other sphingosine-1-phosphate receptor 1 modulators norm… Ozanimod · PMID 41966521 | Sclérose en plaques | Traitement symptomatique | Publication | PubMed | Voir la publication source A key brain structure in the processing of chronic pain is the central nucleus of the amygdala (CeA), which has justifi… | Neuropharmacology 2026-08-16 21:21:54 | Source |
| Massively parallel single-cell chromatin landscapes of human immune c… CBD 200 mg OD · PMID 31375813 | Migraine | Immunomodulation | Publication | PubMed | Voir la publication source Understanding complex tissues requires single-cell deconstruction of gene regulation with precision and scale. Here, we… | Nature biotechnology 2026-08-16 19:26:32 | Source |
| Motor function of the opossum sphincter of Oddi. CBD 200 mg OD · PMID 6822661 | Migraine | À vérifier | Publication | PubMed | Voir la publication source We studied the opossum sphincter of Oddi (SO) because in this species the SO is approximately 3 cm in length and its ex… | The Journal of clinical investigation 2026-08-16 19:26:32 | Source |
| Cannabidiol Attenuates Heroin Seeking in Male Rats Associated With No… CBD 100 mg OD · PMID 40992584 | Migraine | Thérapie génique | Publication | PubMed | Voir la publication source Opioid use disorder is a chronic relapsing condition characterized by cycles of compulsive drug use, abstinence, and re… | Biological psychiatry 2026-08-16 19:26:31 | Source |
| Maternal ingestion of cannabidiol (CBD) in mice leads to sex-dependen… CBD 100 mg OD · PMID 39481653 | Migraine | Thérapie génique | Publication | PubMed | Voir la publication source The consequences of perinatal cannabidiol (CBD) exposure are severely understudied, but are important, given its widesp… | Pharmacology, biochemistry, and behavior 2026-08-16 19:26:31 | Source |
| 1-Deoxynojirimycin attenuates diabetic cardiomyopathy via PI3K/AKT-me… Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Contro… | Migraine | Remyélinisation indirecte / réparation · Neuroprotection | Publication | PubMed | Voir la publication source 1-Deoxynojirimycin (DNJ), a naturally occurring alkaloid derived from mulberry leaves (Morus alba L.), is a powerful α-… | Journal of ethnopharmacology 2026-08-16 19:26:30 | Source |
| Zhenwu Decoction ameliorates experimental benign prostatic hyperplasi… Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Contro… | Migraine | Remyélinisation indirecte / réparation · Neuroprotection · Traitement symptomat… | Publication | PubMed | Voir la publication source Zhenwu Decoction (ZWD), first recorded in the Shang Han Lun, is a classical formula used to warm Yang and promote water… | Journal of ethnopharmacology 2026-08-16 19:26:30 | Source |
| A Randomized Controlled Trial of Instillation Protocols Prior to Intr… onabotulinumtoxinA prophylaxis with Lidocaine · PMID 40025238 | Migraine | Traitement symptomatique | Publication | PubMed | Voir la publication source Achieving adequate pain relief is crucial for intradetrusor onabotulinumtoxinA treatments for idiopathic overactive bla… | International urogynecology journal 2026-08-16 19:26:28 | Source |
| A phase 1, multicenter, open-label study to evaluate the pharmacokine… Rimegepant 75 mg ODT · PMID 41133671 | Migraine | À vérifier | Publication | PubMed | Voir la publication source To evaluate pharmacokinetics (PK), safety, and tolerability of a weight-adjusted dose of rimegepant orally disintegrati… | Headache 2026-08-16 19:26:27 | Source |
| A randomized open-label study to evaluate the effectiveness and safet… Rimegepant 75 mg ODT · PMID 40734466 | Migraine | À vérifier | Publication | PubMed | Voir la publication source AimTo evaluate rimegepant, a calcitonin gene-related peptide receptor antagonist, for short-term prevention of fasting-… | Cephalalgia : an international journal of headache 2026-08-16 19:26:27 | Source |
| Rimegepant for acute treatment of migraine in triptan-unsuitable adul… Rimegepant 75 mg ODT · PMID 41255093 | Migraine | Traitement symptomatique | Publication | PubMed | Voir la publication source BackgroundA subset of individuals with migraine are unsuitable for triptans due to intolerance, lack of efficacy, or co… | Cephalalgia : an international journal of headache 2026-08-16 19:26:27 | Source |
| Decoding the serotonin-alcohol crosstalk: the role of central seroton… Serotonergic Psychedelic · PMID 42329577 | Migraine | À vérifier | Publication | PubMed | Voir la publication source Serotonin (5-hydroxytryptamine; 5-HT) is a key neuromodulator involved in the regulation of mood, appetite, aggression,… | Pharmacological reports : PR 2026-08-16 19:26:26 | Source |
| Proliferative Effects of the Psychedelic N,N-Dimethyltryptamine (DMT)… Serotonergic Psychedelic · PMID 42427129 | Migraine | Thérapie cellulaire | Publication | PubMed | Voir la publication source The serotonergic psychedelic N,N-dimethyltryptamine (DMT) produces rapid antidepressant effects in preclinical and earl… | ACS chemical neuroscience 2026-08-16 19:26:26 | Source |
| Botulinum toxin effects on biochemical biomarkers related to inflamma… Tear Biomarkers for Migraine · PMID 40035830 | Migraine | Neuroprotection · Immunomodulation · Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source Botulinum toxin type A (BoNT) has emerged as a potential alternative to conventional therapies to many debilitating chr… | Journal of neural transmission (Vienna, Austria : 1996) 2026-08-16 19:26:25 | Source |
| Feasibility and Tolerability of Psilocybin for Phantom Limb Pain. Serotonergic Psychedelic · PMID 42567236 | Migraine | Traitement symptomatique | Publication | PubMed | Voir la publication source Phantom limb pain (PLP) is a refractory condition defined by pain experienced in a missing limb. Psilocybin, a classica… | The journal of pain 2026-08-16 19:26:25 | Source |
| The ocular surface tear film as a biomarker for systemic health. Tear Biomarkers for Migraine · PMID 40345388 | Maladie d’Alzheimer · Maladie de Parkinson · Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source The tear film is a complex structure with rich interactions with the human body. A growing body of evidence suggests th… | The ocular surface 2026-08-16 19:26:25 | Source |
| [Clinical practice guideline for migraine with traditional Chinese me… Yangxue Qingnao Granules (Pills) · PMID 33350221 | Migraine | Thérapie génique | Publication | PubMed | Voir la publication source The present clinical practice guideline was written by experts organized by the special group of key projects in the 13… | Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi =… 2026-08-16 19:26:24 | Source |
| [Network Meta-analysis of oral Chinese patent medicine in treatment o… Yangxue Qingnao Granules (Pills) · PMID 32627500 | Migraine | À vérifier | Publication | PubMed | Voir la publication source The efficacy of oral Chinese patent medicine in the treatment of acute cerebral infarction was systematically evaluated… | Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi =… 2026-08-16 19:26:24 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||